Rejecting involution and seeking differences, BPC 2022 will explore a new journey of innovative drug research and development

Session on Innovative Antibody Drugs — Target, Bi / Multispecific / Functional Antibody Drug Early R&D and Druggability / Developability

Innovative Drug Conjugates Session - ADC/X-DC Drug R&D and CMC Development

DAY 1 March 22

Antibody Engineering / Molecular Design and Better Druggability / Developability for Next Development

-Deep -profile double-resistance engineering / design optimization and safety / effectiveness study

- Analysis of PK/PD/ expression / immunogenicity and other difficulties in druggability and development of dual antibodies

-Learn about innovative molecular structure design and druggability research and development of polyclonal antibodies

DAY 1 March 22

" Three Elements and Five Elements " of Differentiated Projects

-Analyze emerging target mechanism research / selection logic and differentiated project approval strategy

-Discuss the key attributes and screening / engineering of better antibodies in ADCs

-Learn about the development and latest progress of new generation coupling methods and platforms

- Master the research and development of more stable / efficient / low toxicity Linker and emerging Payload

DAY 2 March 23

Pathways that reject "involution" / target discovery and combinatorial strategies / biology / mechanisms and early development

- Dig deep into new targets / pathways and differentiated indications for unmet clinical needs

-Explore emerging targets such as NK cells / tumor microenvironment / CD112R /B family biology/MOA

-Analyze target combination logic / validation and drug development based on biological research / translational medicine

DAY 2 March 23

CMC strategy and development of complex structure from 1 to N

-Discuss the process and quality control of ADC preparation / impurity purification / analysis / characterization

- Resolve process scale-up challenges such as uniformity / repeatability

- CMC systematic management and compliance requirements for complex structures

- Mechanism and development of innovative drug conjugates such as PDC/RDC/ISAC

Small Molecule Innovative Drug Discovery and Innovation Forum

Small Molecule Innovative Drug CMC Application and Development Forum

DAY 1 March 22

Targeting unmanufacturable drugs — research and development of small molecule innovative drugs with competitive barriers

- Targeted protein degradation with PROTAC

- Frontier technology pharmaceuticals such as AIDD/CADD/SBDD/FBDD/DEL

DAY 1 March 22

Sprint the last mile - CMC declaration and listing

-Addressing change compliance challenges

- NDA declaration strategy and practice

DAY 2 March 23

Differentiated drug discovery based on clinical needs

-Oncology drug discovery and innovation

- Non-Oncology Drug Discovery and Innovation , Anti-Infection ( COVID and Others) , CNS Nervous System

DAY 2 March 23

Start with the end in mind - small molecule innovative drug pharmacy and process development

-Process optimization and quality analysis of innovative APIs

-Exploration and optimization, process development and quality analysis of high - end chemical preparations

Innovative drug transformation and clinical development, internationalization under new regulations

Indication development and trial design of innovative drugs based on clinical needs

DAY 1 March 22

- China's innovative drug 2.

DAY 2 March 23

-Hot diseases, targets and categories: clinical development under medical science